Spotlight on Clinical Trials
A phase I/II clinical trial of the anti-EGFR monoclonal antibody, panitumumab, and the proteasomal Inhibitor, bortezomib, in patients with advanced, refractory KRAS wild-type colorectal cancer
The purpose of this trial is to study the combination of two agents that have already been FDA-approved as single agents for the treatment of colorectal cancer: an anti-EGFR antibody called panitumumab and drug called bortezomib (a proteasomal inhibitor). Patients with advanced colorectal cancer that is proving difficult to control and has a genetically "normal" KRAS gene (KRAS wild-type) are invited to join this study.
In this study, all patients will receive panitumumab + bortezomib combination therapy. The study will be in two stages. In the first stage, we will work out the ideal dose of each agent combined. In the second stage, patients will receive the ideal doses and if significant disease control is observed, more patients will be enrolled (for a total of 35 patients). Patient tumor size will be assessed by imaging before drug treatment and then every 8 weeks. The mechanism by which bortezomib might enhance panitumumab treatment will be investigated by molecular analysis of patient blood and tumor tissue samples.
See http://lombardi.georgetown.edu/clinicalprotocols/index.cfm for further trial details or contact research coordinator Karen Vogel at email@example.com.